Related Experiment Videos
Experimental animal models for the study of therapeutic approaches in renal cell carcinoma
G G Hillman1, J P Droz, G P Haas
1Department of Urology, Wayne State University School of Medicine, Detroit, MI 48201.
Abstract:
Renal cell cancer is a common malignancy with a poor response to multiple therapeutic modalities. Immunotherapy is the most promising of the various treatment approaches tried. Recently, Interleukin-2 has been approved by the Food and Drug Administration for the treatment of metastatic kidney cancer. However, the relatively low response rate (15-30%) and the limiting toxicity of immunotherapy regimens stress the need to develop new therapeutic modalities. Experimental animal models are instrumental in the development of new treatment alternatives. We describe several of the animal models available for the study of kidney cancer and discuss on-going preclinical investigations in the murine renal adenocarcinoma system (Renca), the Wistar-Lewis rat model, and human renal cancer xenograft models in immunodeficient mice.
Insights
New animal models are crucial for developing better kidney cancer treatments. Current immunotherapies show limited success, highlighting the need for advanced preclinical research using models like Renca.
Area of Science:
- Oncology
- Immunology
- Preclinical Research
Background:
- Renal cell carcinoma (kidney cancer) is a prevalent malignancy with limited treatment options.
- Immunotherapy, including Interleukin-2, shows promise but has low response rates and significant toxicity.
- Development of novel therapeutic strategies is essential for improving patient outcomes.
Purpose of the Study:
- To review existing animal models for kidney cancer research.
- To discuss ongoing preclinical investigations utilizing these models.
- To highlight the importance of animal models in advancing kidney cancer therapeutics.
Main Methods:
- Review of established and novel animal models for renal cell carcinoma.
- Discussion of preclinical studies in murine renal adenocarcinoma (Renca) model.
- Examination of Wistar-Lewis rat model and human renal cancer xenografts in immunodeficient mice.
Main Results:
- Various animal models are available for studying kidney cancer.
- Preclinical investigations are actively exploring new treatment avenues in these models.
- These models facilitate the evaluation of novel therapeutic strategies before clinical application.
Conclusions:
- Animal models are indispensable tools for advancing kidney cancer research.
- Continued development and utilization of preclinical models are vital for discovering effective treatments.
- Further research in models like Renca and xenografts may lead to improved therapies for renal cell carcinoma.